Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

CSV to CSA: From Compliance to Confidence

Introduction

Ensuring the quality and reliability of digital systems is a constant challenge in the life sciences, where we know that the consequences of even the smallest misstep can be devastating. For decades, Computer System Validation (CSV) has been the preferred method for achieving this goal. It’s like a sturdy tightrope, constructed with great care to ensure that a system meets all regulatory requirements. However, we also understand that this traditional approach, while effective, can be cumbersome and time-consuming.

A more flexible approach to validation is needed in the ever-changing software and technology industry. Have you heard of Computer Software Assurance (CSA)? It’s a modern methodology gaining traction in the life sciences industry. CSA can be thought of as a high-tech tightrope, using advanced risk management techniques to navigate the validation process with greater efficiency and confidence. In this blog post, we’ll explore the key differences between CSV and CSA, as well as the benefits and framework of the CSA methodology.

CSV: A Tried-and-True Method, But is it Time for an Upgrade?

CSV is the bedrock of software validation in the life sciences industries. It ensures that a system meets all regulatory requirements through a well-defined set of procedures. This rigorous process typically involves:

  • Detailed Requirement Analysis:

    Computerized system validation starts by meticulously defining the intended use and functionalities of the software system. This ensures that validation activities are tailored to the specific purpose of the system.

  • Comprehensive Testing:

    It emphasizes thorough testing of all system functionalities to identify any potential deviations or errors. This testing covers a wide range of scenarios, aiming to leave no stone unturned.

  • Exhaustive Documentation:

    Every step of the validation process is meticulously and extensively documented. This documentation serves as evidence for regulatory bodies and demonstrates the system’s compliance.

For more information on CSV, check out Computer System Validation: Key Strategies for Compliance.
CSV A tried and true method
CSV is a well established process, but is it time for a CSA transition now?

Limitations of the CSV Approach

There’s no denying the value of CSV. It has a proven track record of ensuring the quality and reliability of countless software systems within the life sciences domain. Some of its key strengths also include auditability, traceability and being widely accepted. However, as the software landscape evolves rapidly, the limitations of CSV become more apparent:

While effective, CSV’s limitations highlight the need for CSA’s more adaptable, efficient approach, emphasizing risk management over exhaustive documentation.

The Emergence of CSA

The Food and Drug Administration’s (FDA) transition from CSV to CSA represents a significant change in the life sciences industry, highlighting a more efficient approach to software validation. This change is supported by the FDA’s draft guidance on ‘Computer Software Assurance for Production and Quality System Software‘. 

CSA prioritizes critical functionalities and leverages a risk-based approach to streamline the validation process. It also addresses common challenges associated with traditional CSV, such as automation roadblocks and redundant testing. Here’s a closer look at the core principles that set CSA apart:

Emergence of CSA for streamlining compliance in the digital era.
Emergence of CSA for streamlining compliance in the digital era.

CSA prioritizes risk assessment in validation, focusing on critical functionalities affecting patient safety and data integrity. This targeted approach ensures validation efforts are concentrated on the areas with the most significant consequences.

CSA moves beyond simply testing every feature as it aims to validate intended outcomes. It streamlines the process by focusing on evidence that the system works as designed and ensures data integrity, thereby reducing unnecessary testing.

The life sciences industry is constantly evolving, and software is no exception. CSA’s risk-based approach readily adapts to these changes. When new functionalities are added or technologies are updated, a fresh risk assessment can be conducted to ensure continued system effectiveness. This flexibility ensures the validation process remains relevant in the face of constant innovation.

This approach aims to reduce burdensome documentation and paperwork, supporting agile software development life cycle (SDLC) methodology, and leveraging vendor documentation and testing.

Need Expert Guidance on CSV/CSA?

Setup an appointment

Key Differences Between CSV and CSA​

 

CSV

CSA

Focus and Approach

A linear risk-based approach that ensures intended use is met and computerized systems are compliant with relevant regulations.  

Addresses the same purpose as CSV but with a more dynamic risk-based approach, leveraging critical thinking and targeted testing; Focusses on the process and patient rather than software-centric risks.

Documentation and Efficiency

Significant volume of paperwork; Time-consuming and resource intensive.

Fewer generated documents without compromise on quality or compliance.

Risk Assessment and Testing

Though risk-based, it involves more comprehensive coverage and detailed documented testing.

Assurance activities are based on the risk posed by the software features/functions; Allows more flexibility and reduced overall cycle time for testing of low-risk areas (through unscripted testing options).

Key steps of the CSA Framework

The first step lays the groundwork for the entire risk-based strategy. Here, manufacturers meticulously define the role of each software program within the production or quality system. This involves understanding how the software interacts with other systems, the data it handles, and its ultimate impact on the final medical device.

Imagine a medical device manufacturer uses two software programs:

  • Program A: Manages basic inventory control for raw materials.
  • Program B: Controls the critical algorithms used during device sterilization.

 

Program A has minimal impact on the final device, while Program B directly affects patient safety. Here, identifying the intended use for each program allows the manufacturer to categorize their risk level.

This step involves a thorough assessment of potential risks associated with the software/function/operation. Here are some factors to consider:

  • Impact on Device Functionality:

    Does the software directly influence the device’s performance or safety features? For instance, software controlling dosage delivery in a medication pump would require a more rigorous assessment compared to a program managing shipping logistics.

  • Data Integrity:

    Can the software manipulate or compromise data related to production or quality control? If the software manages patient data or sterilization records, a data breach could have serious consequences. The risk assessment would emphasize the need for robust security measures.

  • Security Vulnerabilities:

    Is the software susceptible to hacking or cyberattacks that could disrupt operations? Software connected to the internet or handling sensitive data would necessitate a thorough evaluation of potential security weaknesses.

By considering these factors, the manufacturer can assign a risk level (high, medium, low) to each software program. This risk stratification forms the foundation for selecting the most appropriate validation activities.

Based on the assigned risk level, the manufacturer chooses the most suitable assurance activities (including scripted and unscripted testing). Here’s a breakdown of potential activities for different risk categories:

  • High-Risk Software:

    This software requires the most rigorous validation methods. Examples include code reviews, extensive unit testing, integration testing, and penetration testing to identify security weaknesses.

  • Medium-Risk Software:

    Validation for this category might involve a combination of code reviews, selective unit testing, and functional testing to ensure the software performs as intended.

  • Low-Risk Software:

    For low-risk software, simpler validation methods like user acceptance testing (confirming the software meets user needs) might be sufficient.

The CSA Framework hinges on comprehensive records. These records document the entire software assurance process, ensuring transparency and facilitating audits. Automation tools can be used to streamline testing and documentation processes. Here are some of the key information that the documentation capture:

  • Intended Use:
    A clear description of the software’s role in the system, including its tasks, data interaction, and integration.
  • Risk Assessment:
    Documentation of the risk assessment process, detailing identified hazards, assigned risk levels, and the rationale behind them.
  • Validation Activities:
    A record of chosen validation methods for each software program, justifying their selection based on risk level, with details on test plans and procedures.
  • Validation Results:
    Records of pass/fail status for each test, along with any discrepancies, deviations, and corrective actions.
  • Traceability Matrix:
    A link between identified risks, chosen validation activities, and their results, demonstrating how each risk is mitigated.

 

These records are maintained throughout the software’s lifecycle, with updates for modifications, periodic reviews, and continued risk assessment adherence. Comprehensive records are the foundation for a successful CSA Framework implementation, fostering trust with the FDA and prioritizing patient safety.

Implementation Challenges and Considerations of CSA

As we embark on the transition from CSV to CSA, several implementation challenges and considerations emerge. Addressing these effectively is crucial for a smooth transition:

Common Roadblocks
  • Compliance Mindset
    The fear of change due to a deep-rooted compliance mindset, prioritizing checklists and documentation over practical, need-based actions.
  • Digital Transition
    The challenge of moving from paper-based to digital CSA principles, especially for companies entrenched in traditional processes.
Cultural and Process Shifts
Leadership Support 

Success in updating to CSA processes demands high-level leadership to champion the cause, breaking the compliance mindset and advocating for the cultural shift towards a more efficient, risk-based approach.

Solutions for Efficiency
  • Embrace Technology

    Implementing cloud-based technologies (which has already gained traction) and automated workflows can significantly enhance efficiency, reducing manual errors and improving real-time data accessibility.

  • Regulatory Compliance

    Investing in modern regulatory intelligence platforms and automated Quality Management Systems (eQMS) software ensures adherence to rigorous standards set by regulatory bodies like the FDA and European Medicines Agency (EMA).

  • Quality Management

    Developing a risk-based approach to QMS focuses efforts on high-risk areas, optimizing resource allocation and ensuring product quality and patient safety.

Identify and address challenges in implementation while moving from CSV to CSA.
Identify and address challenges in implementation while moving from CSV to CSA.

Case Study: Risk-Based Assurance for a Learning Management System

Hypothetically, a manufacturer is rolling out a COTS Learning Management System (LMS) to automate training management, recording, tracking, and reporting in compliance with regulatory requirements (21 CFR 820.25). The system’s key functionalities include user login, training assignment, training completion evidence, notifications of training assignments/completion, and generation of training reports.

The manufacturer applied a risk-based assurance strategy to efficiently validate the LMS. By focusing on critical features and employing targeted testing methods, the manufacturer ensured the system’s integrity and compliance while documenting essential validations and outcomes. This approach streamlined the assurance process without compromising on thoroughness or regulatory obligations.

Conclusion

The transition from CSV to CSA marks a pivotal shift towards efficiency and a further emphasis on risk-based approach in the life sciences sector, prioritising patient safety and product quality. Moving beyond heavy documentation, this change represents a deeper shift in the industry’s mindset towards agility and critical thinking in regulatory compliance. Despite the challenges of adoption, the benefits – improved operational efficiency, resource optimisation and innovation – underscore CSA’s critical role in refining quality management systems. This will improve not only operational efficiency, but also the development of reliable and safe life science products, ushering in a new era of patient-centred healthcare technology.

References

Nirekshana Krishnasagar

Nirekshana Krishnasagar

Computer Systems Validation Specialist